I-1-deficiency negatively impacts survival in a cardiomyopathy mouse model

Aims: Hypertrophic cardiomyopathy (HCM) is characterized by left ventricular hypertrophy, diastolic dysfunction and increased interstitial fibrosis. Current treatment is based on beta-adrenoceptor (AR) and calcium channel blockers. Since mice deficient of protein phosphatase-1 inhibitor-1 (I-1), an...

Full description

Bibliographic Details
Published in:International Journal of Cardiology: Heart & Vasculature
Main Authors: Felix W. Friedrich, Hannieh Sotoud, Birgit Geertz, Silvio Weber, Frederik Flenner, Silke Reischmann, Thomas Eschenhagen, Lucie Carrier, Ali El-Armouche
Format: Article
Language:English
Published: Elsevier 2015-09-01
Subjects:
Beta-adrenergic signalling
Cardiomyopathy
Hypertrophy
Hypertrophic cardiomyopathy
Online Access:http://www.sciencedirect.com/science/article/pii/S2352906715300026

Internet

http://www.sciencedirect.com/science/article/pii/S2352906715300026

Similar Items